Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $256.59 USD
Change Today -0.51 / -0.20%
Volume 615.1K
PCYC On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for pharmacyclics inc (PCYC)

Pharmacyclics Inc. has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total $845.0M USD. Accounts Receivable are among the industry's worst with 38.16 days worth of sales outstanding. This implies that revenues are not being collected in an efficient manner. Last, Pharmacyclics Inc. is among the least efficient in its industry at managing inventories, with 19.56 days of its Cost of Goods Sold tied up in Inventories.
Currency in
Millions of US Dollars
As of:Jun 30
2011
Reclassified
Dec 31
2012
Restated
Dec 31
2013
Dec 31
2014
4 Year
Trend
Assets    
Cash and Equivalents87.8307.4624.0845.0
Short-Term Investments24.69.711.712.0
TOTAL CASH AND SHORT TERM INVESTMENTS112.3317.1635.6857.0
Accounts Receivable0.026.763.089.6
Other Receivables------1.7
TOTAL RECEIVABLES0.026.763.091.3
Inventory----12.634.4
Prepaid Expenses2.32.79.320.6
Other Current Assets----20.312.3
TOTAL CURRENT ASSETS114.7346.5740.81,015.6
Gross Property Plant and Equipment10.215.033.244.1
Accumulated Depreciation-8.9-8.6-7.7-11.6
NET PROPERTY PLANT AND EQUIPMENT1.36.425.532.5
Other Intangibles------8.7
Other Long-Term Assets0.32.22.53.3
TOTAL ASSETS116.4355.1768.81,060.1
    
LIABILITIES & EQUITY    
Accounts Payable0.94.64.07.3
Accrued Expenses5.611.765.685.0
Current Income Taxes Payable--1.41.40.1
Other Current Liabilities, Total0.83.59.083.1
Unearned Revenue, Current7.08.17.618.8
TOTAL CURRENT LIABILITIES14.329.387.6194.2
Unearned Revenue, Non-Current--62.652.034.9
Other Non-Current Liabilities0.40.81.51.8
TOTAL LIABILITIES14.792.6141.1230.9
Common Stock0.00.00.00.0
Additional Paid in Capital514.8546.1844.2959.6
Retained Earnings-413.1-283.6-216.6-130.5
Comprehensive Income and Other0.00.00.00.0
TOTAL COMMON EQUITY101.7262.5627.6829.2
TOTAL EQUITY101.7262.5627.6829.2
TOTAL LIABILITIES AND EQUITY116.4355.1768.81,060.1
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCYC:US $256.59 USD -0.51

PCYC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.126.60 CHF -0.30
Alexion Pharmaceuticals Inc $180.08 USD -4.50
BioMarin Pharmaceutical Inc $120.28 USD -2.67
Genmab A/S kr555.00 DKK +9.50
Vertex Pharmaceuticals Inc $133.20 USD -2.62
View Industry Companies
 

Industry Analysis

PCYC

Industry Average

Valuation PCYC Industry Range
Price/Earnings 100.0x
Price/Sales 26.6x
Price/Book 23.5x
Price/Cash Flow 227.4x
TEV/Sales 25.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMACYCLICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.